Across TCGA pan-cancer cohorts, AADACL4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AADACL4 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher AADACL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AADACL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
SARC, BRCA, and LGG are the cancer types where AADACL4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.